Artelo Biosciences (Artelo Biosciences) Net Change in Cash : $-6.29 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Artelo Biosciences's Net Change in Cash for the three months ended in Mar. 2024 was $-1.62 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.29 Mil.

Artelo Biosciences Net Change in Cash Historical Data

The historical data trend for Artelo Biosciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Net Change in Cash Chart

Artelo Biosciences Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

4.09

-2.28

4.49

-5.27

-4.07

Artelo Biosciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															0.03	-1.20	-3.62	0.14	-1.62

Artelo Biosciences Net Change in Cash Calculation

Artelo Biosciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-8.207	+	3.507	+	0.567	+	0.06
	=	-4.07

Artelo Biosciences's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -2.942 + 1.269 + 0.055 + -0.002

= -1.62

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artelo Biosciences Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Artelo Biosciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences (Artelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Net Change in Cash

Comparable Companies

ARDS REVB FWBI ELOX QLGN SXTP PTIX APVO GRI ENVB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ARTL:USA

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Artelo Biosciences (Artelo Biosciences) Headlines

From GuruFocus

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
By Marketwired • 09-06-2023

Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
By sperokesalga sperokesalga • 05-11-2023

Artelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th
By GuruFocusNews GuruFocusNews • 07-05-2022

Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
By Value_Insider Value_Insider • 11-08-2022

Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
By sperokesalga sperokesalga • 04-25-2023

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
By Marketwired • 09-07-2023

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
By Stock market mentor Stock market mentor • 02-02-2023

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
By Marketwired • 10-04-2023

Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
By PurpleRose PurpleRose • 07-14-2022

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
By Marketwired • 07-19-2023